Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTangible Book ValueTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewGenIvf (NIVF) Other Accumulated Expenses (2022 - 2024)

Historic Other Accumulated Expenses for NewGenIvf (NIVF) over the last 3 years, with Q4 2024 value amounting to $154.5 billion.

  • NewGenIvf's Other Accumulated Expenses rose 35398197778.52% to $154.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $154.5 billion, marking a year-over-year increase of 35398197778.52%. This contributed to the annual value of $154.5 billion for FY2024, which is 35398197778.52% up from last year.
  • According to the latest figures from Q4 2024, NewGenIvf's Other Accumulated Expenses is $154.5 billion, which was up 35398197778.52% from $43633.0 recorded in Q4 2023.
  • NewGenIvf's 5-year Other Accumulated Expenses high stood at $154.5 billion for Q4 2024, and its period low was $22345.0 during Q4 2022.
  • Its 3-year average for Other Accumulated Expenses is $51.5 billion, with a median of $43633.0 in 2023.
  • In the last 5 years, NewGenIvf's Other Accumulated Expenses skyrocketed by 9526.96% in 2023 and then soared by 35398197778.52% in 2024.
  • Quarter analysis of 3 years shows NewGenIvf's Other Accumulated Expenses stood at $22345.0 in 2022, then skyrocketed by 95.27% to $43633.0 in 2023, then soared by 353981977.79% to $154.5 billion in 2024.
  • Its Other Accumulated Expenses was $154.5 billion in Q4 2024, compared to $43633.0 in Q4 2023 and $22345.0 in Q4 2022.